David A Power

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9088045/publications.pdf

Version: 2024-02-01

87 papers 5,412 citations

39 h-index 79698 73 g-index

87 all docs

87 docs citations

87 times ranked 7228 citing authors

#	Article	IF	CITATIONS
1	Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways. Diabetes, 2022, 71, 1282-1298.	0.6	14
2	Blocking AMPK signalling to acetyl-CoA carboxylase increases cisplatin-induced acute kidney injury and suppresses the benefit of metformin. Biomedicine and Pharmacotherapy, 2022, 153, 113377.	5.6	4
3	Serum potassium abnormalities in chronic kidney disease: prevalence, patient characteristics and clinical outcomes. Internal Medicine Journal, 2021, 51, 1906-1918.	0.8	2
4	Dialysis and driving: an anonymous survey of patients receiving dialysis for endâ€stage kidney disease. Internal Medicine Journal, 2021, 51, 1691-1699.	0.8	0
5	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility. Diabetes, 2020, 69, 83-98.	0.6	48
6	Mutation of regulatory phosphorylation sites in PFKFB2 worsens renal fibrosis. Scientific Reports, 2020, 10, 14531.	3.3	16
7	485-P: T Lymphocytes Infiltration in Kidneys of People with Type 2 Diabetes. Diabetes, 2020, 69, 485-P.	0.6	O
8	Absence of the \hat{I}^21 subunit of $\langle scp \rangle AMP \langle scp \rangle \hat{a} \in \hat{a}$ ctivated protein kinase reduces myofibroblast infiltration of the kidneys in early diabetes. International Journal of Experimental Pathology, 2019, 100, 114-122.	1.3	2
9	Three Dimensional Glomerular Reconstruction: A Novel Approach to Evaluate Renal Microanatomy in Diabetic Kidney Disease. Scientific Reports, 2019, 9, 1829.	3.3	4
10	Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction. American Journal of Transplantation, 2019, 19, 1037-1049.	4.7	71
11	Malignant Hypertension Causing a Pulmonary-Renal Syndrome. Case Reports in Nephrology, 2018, 2018, 1-4.	0.4	O
12	Pre-eclampsia is associated with altered expression of the renal sodium transporters NKCC2, NCC and ENaC in urinary extracellular vesicles. PLoS ONE, 2018, 13, e0204514.	2.5	31
13	Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin. Journal of the American Society of Nephrology: JASN, 2018, 29, 2326-2336.	6.1	93
14	Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature, 2017, 545, 243-247.	27.8	181
15	NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. Diabetes, 2017, 66, 2691-2703.	0.6	119
16	Introduction of Renal Key Performance Indicators Associated with Increased Uptake of Peritoneal Dialysis in a Publicly Funded Health Service. Peritoneal Dialysis International, 2017, 37, 198-204.	2.3	7
17	Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis. Diabetes, 2016, 65, 1085-1098.	0.6	47
18	Balancing the energy equation for healthy kidneys. Journal of Pathology, 2015, 237, 407-410.	4. 5	14

#	Article	IF	CITATIONS
19	The Thiazide-Sensitive Co-Transporter Promotes the Development of Sodium Retention in Mice with Diet-Induced Obesity. Kidney and Blood Pressure Research, 2015, 40, 509-519.	2.0	9
20	Obesity-Related Chronic Kidney Diseaseâ€"The Role of Lipid Metabolism. Metabolites, 2015, 5, 720-732.	2.9	52
21	Implementation of renal key performance indicators: Promoting improved clinical practice. Nephrology, 2015, 20, 184-193.	1.6	19
22	AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney International, 2014, 85, 191-197.	5.2	60
23	Activation of AMPK reduces the co-transporter activity of NKCC1. Molecular Membrane Biology, 2014, 31, 95-102.	2.0	10
24	Novel mechanisms of Na ⁺ retention in obesity: phosphorylation of NKCC2 and regulation of SPAK/OSR1 by AMPK. American Journal of Physiology - Renal Physiology, 2014, 307, F96-F106.	2.7	28
25	Use of Copy Number Deletion Polymorphisms to Assess DNA Chimerism. Clinical Chemistry, 2014, 60, 1105-1114.	3.2	20
26	Abnormal Processing of Autophagosomes in Transformed B Lymphocytes from SCARB2-Deficient Subjects. BioResearch Open Access, 2013, 2, 40-46.	2.6	9
27	AMPK couples plasma renin to cellular metabolism by phosphorylation of ACC1. American Journal of Physiology - Renal Physiology, 2013, 305, F679-F690.	2.7	18
28	Renal Structure in Normoalbuminuric and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function. Diabetes Care, 2013, 36, 3620-3626.	8.6	178
29	The Outcome of Renal Ischemia-Reperfusion Injury Is Unchanged in AMPK-β1 Deficient Mice. PLoS ONE, 2012, 7, e29887.	2.5	27
30	Vision-Threatening Retinal Abnormalities in Chronic Kidney Disease Stages 3 to 5. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1866-1871.	4.5	65
31	5â€aminoimidazoleâ€4â€carboxamide ribonucleoside and AMPâ€activated protein kinase inhibit signalling through NFâ€₽B. Immunology and Cell Biology, 2010, 88, 754-760.	2.3	50
32	Corticosteroids Worsen Proteinuria and Increase Intraglomerular Signaling by NF-Ä,B in a Model of Membranous Glomerulonephritis. Nephron Experimental Nephrology, 2010, 116, e23-e31.	2.2	6
33	Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. American Journal of Physiology - Renal Physiology, 2010, 298, F1067-F1077.	2.7	126
34	Low salt concentrations activate AMP-activated protein kinase in mouse macula densa cells. American Journal of Physiology - Renal Physiology, 2009, 296, F801-F809.	2.7	13
35	Abnormal Renal Function and Electrolyte Disturbances in Older People. Journal of Pharmacy Practice and Research, 2009, 39, 230-234.	0.8	1
36	Array-Based Gene Discovery with Three Unrelated Subjects Shows SCARB2/LIMP-2 Deficiency Causes Myoclonus Epilepsy and Glomerulosclerosis. American Journal of Human Genetics, 2008, 82, 673-684.	6.2	230

#	Article	IF	CITATIONS
37	Renal ageing: Changes in the cellular mechanism of energy metabolism and oxidant handling (Review) Tj ETQq1	l 0,784314 1.6	rgBT /Over
38	Bradykinin stimulates endothelial cell fatty acid oxidation by CaMKK-dependent activation of AMPK. Atherosclerosis, 2008, 200, 28-36.	0.8	45
39	Predictors of Early Dialysis Vascular-Access Failure after Thrombolysis. American Journal of Nephrology, 2008, 28, 181-189.	3.1	10
40	Lowering of Proteinuria in Response to Antihypertensive Therapy Predicts Improved Renal Function in Late but Not in Early Diabetic Nephropathy: A Pooled Analysis. American Journal of Nephrology, 2008, 28, 614-627.	3.1	47
41	Biological Drugs and the Coming of Biosimilars. Journal of Pharmacy Practice and Research, 2008, 38, 137-139.	0.8	5
42	Induction of Passive Heymann Nephritis in Complement Component 6-Deficient PVG Rats. Journal of Immunology, 2007, 179, 172-178.	0.8	55
43	Regulation of the renal-specific Na+–K+–2Clâ [^] co-transporter NKCC2 by AMP-activated protein kinase (AMPK). Biochemical Journal, 2007, 405, 85-93.	3.7	83
44	Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. Journal of Molecular and Cellular Cardiology, 2007, 42, 271-279.	1.9	453
45	Probiotic treatment of vancomycinâ€resistant enterococci: a randomised controlled trial. Medical Journal of Australia, 2007, 186, 454-457.	1.7	119
46	Phosphorylation of Neuronal and Endothelial Nitric Oxide Synthase in the Kidney with High and Low Salt Diets. Nephron Physiology, 2006, 102, p36-p50.	1.2	22
47	Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells. Immunology and Cell Biology, 2006, 84, 6-12.	2.3	21
48	Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrology Dialysis Transplantation, 2006, 21, 1611-1617.	0.7	44
49	Is Nonalbuminuric Renal Insufficiency in Type 2 Diabetes Related to an Increase in Intrarenal Vascular Disease?. Diabetes Care, 2006, 29, 1560-1566.	8.6	124
50	New insights into the molecular biology of the glomerular filtration barrier and associated disease. Review Article. Nephrology, 2005, 10, 157-166.	1.6	29
51	Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology, 2005, 10, 167-173.	1.6	44
52	Acute renal ischemia rapidly activates the energy sensor AMPK but does not increase phosphorylation of eNOS-Ser ¹¹⁷⁷ . American Journal of Physiology - Renal Physiology, 2005, 289, F1103-F1115.	2.7	61
53	Regulation of the energy sensor AMP-activated protein kinase in the kidney by dietary salt intake and osmolality. American Journal of Physiology - Renal Physiology, 2005, 288, F578-F586.	2.7	63
54	A Synthetic Heparanase Inhibitor Reduces Proteinuria in Passive Heymann Nephritis. Journal of the American Society of Nephrology: JASN, 2004, 15, 2882-2892.	6.1	58

#	Article	IF	CITATIONS
55	Heparanase Is Involved in the Pathogenesis of Proteinuria as a Result of Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2004, 15, 68-78.	6.1	86
56	A Study of VEGF and Its Receptors in Two Rat Models of Proteinuria. Nephron Physiology, 2004, 96, p26-p36.	1.2	16
57	Unrecognized Anemia in Patients With Diabetes. Diabetes Care, 2003, 26, 1164-1169.	8.6	291
58	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. Kidney International, 2002, 61, 1696-1706.	5.2	49
59	Human Factor H-related Protein 5 (FHR-5). Journal of Biological Chemistry, 2001, 276, 6747-6754.	3.4	67
60	Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney International, 2001, 60, 1287-1296.	5.2	61
61	HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration. Kidney International, 2001, 59, 614-624.	5.2	39
62	Activation of nuclear factor- \hat{l}^eB by podocytes in the autologous phase of passive Heymann nephritis. Kidney International, 2001, 59, 923-931.	5.2	48
63	Coordinated Control of Endothelial Nitric-oxide Synthase Phosphorylation by Protein Kinase C and the cAMP-dependent Protein Kinase. Journal of Biological Chemistry, 2001, 276, 17625-17628.	3.4	484
64	Redistribution of cytoplasmic VEGF to the basolateral aspect of renal tubular cells in ischemia-reperfusion injury. Kidney International, 2000, 57, 2445-2456.	5.2	56
65	Inhibition of heparin-binding epidermal growth factor-like growth factor increases albuminuria in puromycin aminonucleoside nephrosis. Kidney International, 2000, 58, 1098-1107.	5.2	12
66	Transcription factor NF-kappaB in glomerulonephritis. Nephrology, 2000, 5, 71-82.	1.6	10
67	Inhibition with Antisense Oligonucleotide Suggests that lκB-α Does Not Form a Negative Autoregulatory Loop for NF-κB in Mesangial Cells. Nephron Experimental Nephrology, 2000, 8, 144-151.	2.2	15
68	Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. American Journal of Physiology - Renal Physiology, 2000, 278, F905-F915.	2.7	106
69	TUBULOINTERSTITIAL NEPHRITIS FOLLOWING HIGH-DOSE IFOSFAMIDE IN THREE BREAST CANCER PATIENTS. Pathology, 2000, 32, 166-170.	0.6	9
70	Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. Kidney International, 1999, 55, 2310-2321.	5.2	23
71	AMPâ€activated protein kinase phosphorylation of endothelial NO synthase. FEBS Letters, 1999, 443, 285-289.	2.8	729
72	Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. Kidney International, 1998, 53, 1162-1171.	5.2	29

#	Article	IF	CITATIONS
73	AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Letters, 1997, 409, 452-456.	2.8	112
74	Importance of the tubulointerstitium in human glomerulonephritis. II. Distribution of integrin chains \hat{l}^21 , $\hat{l}\pm1$ to 6 and $\hat{l}\pm V$. Kidney International, 1997, 52, 103-110.	5.2	39
75	Adhesion molecule interactions in human glomerulonephritis: Importance of the tubulointerstitium. Kidney International, 1996, 49, 127-134.	5.2	56
76	CD44 in glomerulonephritis: Expression in human renal biopsies, the Thy 1.1 model, and by cultured mesangial cells. Kidney International, 1996, 50, 272-281.	5.2	39
77	Membranous glomerulonephritis associated with hepatitis C virus infection in an adolescent. Pathology, 1994, 26, 399-402.	0.6	17
78	Urokinase-plasminogen activator is synthesized in vitro by human glomerular epithelial cells but not by mesangial cells. Kidney International, 1994, 45, 43-47.	5.2	18
79	A Human Lymphocytotoxic Autoantibody Is Encoded By Antibody Vairable Region Genes In Their Germ Line Configuration. Transplantation, 1993, 56, 1236-1241.	1.0	3
80	An immunohistological study of epidermal growth factor receptor and neu receptor expression in proliferative glomerulonephritis. Pathology, 1993, 25, 327-332.	0.6	11
81	Establishing a Normal Baseline for Immunohistochemical Studies of the Kidney. Nephron, 1992, 62, 479-479.	1.8	O
82	Elevation of albumin synthesis rates in nephrotic patients measured with [1-13C]leucine. Kidney International, 1992, 41, 132-138.	5.2	40
83	Monoclonal antibodies to cultured human glomerular mesangial cells. I. Reactivity with haematopoietic cells and normal kidney sections. Journal of Pathology, 1991, 163, 265-272.	4.5	19
84	THE EFFECT OF CYCLOSPORINE ON HUMORAL AND CELLULAR ALLOREACTIVITY TO ALLOGENEIC PREGNANCY IN RATS. Transplantation, 1986, 42, 400-402.	1.0	2
85	EVIDENCE THAT PROTECTIVE Fc-RECEPTOR-BLOCKING ANTIBODIES IN RENAL TRANSPLANTATION ARE ALLOANTIBODIES NOT AUTOANTIBODIES. Transplantation, 1985, 39, 520-522.	1.0	6
86	Non-Cytotoxic Alloantibodies Defined by the EA Rosette Inhibition Assay. International Archives of Allergy and Immunology, 1984, 74, 324-331.	2.1	2
87	Diagnostic value of urinary N-acetyl- \hat{l}^2 -d-glucosaminidase, its isoenzymes and the fractional excretion of sodium following renal transplantation. Clinica Chimica Acta, 1983, 130, 369-376.	1.1	25